Tasca Therapeutics is developing small molecule inhibitors targeting novel lipid-binding pockets on proteins to create effective treatments for hard-to-treat oncology indications. This approach aims to expand the druggable proteome, providing oncologists with new therapeutic options for challenging cancer cases.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer treatments face challenges due to the limited number of druggable targets on proteins, hindering the development of effective therapies for various oncology indications. This limitation restricts the therapeutic options available to oncologists, especially for hard-to-treat cancers.
Solution
Tasca Therapeutics is developing small molecule inhibitors that target previously unexplored lipid-binding pockets on proteins. By expanding the druggable proteome, Tasca aims to create novel therapeutic options for challenging cancer cases. Their unique drug discovery platform identifies and maps these novel lipid-binding pockets, enabling the design of new medicines to treat cancer patients. This approach offers the potential to overcome resistance mechanisms and improve treatment outcomes in oncology.
Target Audience
The primary target audience includes oncologists and cancer researchers seeking new therapeutic options for patients with difficult-to-treat cancers.
Features
- Identification and mapping of novel lipid-binding pockets on proteins using a proprietary drug discovery platform.
- Development of small molecule inhibitors specifically designed to bind to these lipid-binding pockets.
- Focus on hard-to-treat oncology indications with limited existing therapeutic options.
- Expansion of the druggable proteome to create new targets for cancer therapy.